September 28, 2026- Abbott announced new data showing that the use of continuous glucose monitoring (CGM), including Libre technology, was associated with a lower risk of death and cardiovascular complications among adults with Type 2 diabetes using basal insulin therapy. In this large, real-world study, CGM use was linked to a 45% lower risk of death at 12 months and a 36% lower risk at 24 months. A separate study involving more than 253,000 people with Type 2 diabetes showed using Libre technology nearly halved acute diabetes-event hospitalizations among adults with Type 2 diabetes on basal insulin. Data from both studies will be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), which begins Sept. 28 in Milan, Italy.